NKGen Biotech

NKGen Biotech Net Change in Cash

The Net Change in Cash of NKGen Biotech (NKGN) as of Nov 22, 2026 is 1.70 M USD. In the previous year, Net Change in Cash was 159,000.00 USD — a change of 968.55% (higher).

Net Change in Cash

1.70 MUSD

YoY

968.55%

Last updated:

Net Change in Cash of NKGen Biotech is 2025 1.70 M USD. Net Change in Cash of NKGen Biotech was 2024 159,000.00 USD. It decreases by 968.55% higher compared to the previous year.

The NKGen Biotech Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2021
152,000.00 USD
Jan 1, 2022
-234,000.00 USD
Jan 1, 2023
159,000.00 USD
Jan 1, 2025
1.70 M USD
The NKGen Biotech Net Change in Cash history
YEARNet Change in CashYoY
1.70 MUSD+968.55%
159,000.00USD-167.95%
-234,000.00USD-253.95%
152,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Net Change in Cash of NKGen Biotech is 1.70 M USD in 2025.

Net Change in Cash of NKGen Biotech changed from 159,000.00 USD to 1.70 M USD, representing a 968.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's NKGen Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NKGen Biotech

All Key Metrics — NKGen Biotech